- Home
- ORGN vs OPTN Comparison
ORGN vs OPTN Comparison
Compare ORGN & OPTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORGN
- OPTN
- Stock Information
- Founded
- ORGN 2008
- OPTN 2010
- Country
- ORGN United States
- OPTN United States
- Employees
- ORGN N/A
- OPTN N/A
- Industry
- ORGN Major Chemicals
- OPTN Biotechnology: Pharmaceutical Preparations
- Sector
- ORGN Industrials
- OPTN Health Care
- Exchange
- ORGN Nasdaq
- OPTN Nasdaq
- Market Cap
- ORGN 124.1M
- OPTN 117.6M
- IPO Year
- ORGN N/A
- OPTN 2017
- Fundamental
- Price
- ORGN $1.48
- OPTN $0.71
- Analyst Decision
- ORGN Strong Buy
- OPTN Strong Buy
- Analyst Count
- ORGN 1
- OPTN 2
- Target Price
- ORGN $3.00
- OPTN $4.00
- AVG Volume (30 Days)
- ORGN 1.3M
- OPTN 516.5K
- Earning Date
- ORGN 11-07-2024
- OPTN 11-07-2024
- Dividend Yield
- ORGN N/A
- OPTN N/A
- EPS Growth
- ORGN N/A
- OPTN N/A
- EPS
- ORGN N/A
- OPTN N/A
- Revenue
- ORGN $34,061,000.00
- OPTN $75,058,000.00
- Revenue This Year
- ORGN $10.62
- OPTN $24.44
- Revenue Next Year
- ORGN $175.99
- OPTN $49.00
- P/E Ratio
- ORGN N/A
- OPTN N/A
- Revenue Growth
- ORGN 295.97
- OPTN 3.91
- 52 Week Low
- ORGN $0.44
- OPTN $0.65
- 52 Week High
- ORGN $1.90
- OPTN $2.10
- Technical
- Relative Strength Index (RSI)
- ORGN 49.11
- OPTN 33.40
- Support Level
- ORGN $1.50
- OPTN $0.65
- Resistance Level
- ORGN $1.69
- OPTN $0.70
- Average True Range (ATR)
- ORGN 0.13
- OPTN 0.05
- MACD
- ORGN -0.04
- OPTN -0.00
- Stochastic Oscillator
- ORGN 14.29
- OPTN 24.67
About ORGN Origin Materials Inc.
Origin Materials Inc is a carbon-negative materials company. The platform turns the carbon found in biomass into useful materials, while eliminating the need for fossil resources and capturing carbon in the process. Its products include, PET circular caps and closures, Para-xylene, carbon black, Levulinic acid among others.
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. Its product includes XHANCE (fluticasone propionate) nasal spray, 93 micrograms, a therapeutic utilizing its proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The XHANCE is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by intranasal steroids.